UPDATE: Canaccord Genuity Starts NewLink Genetics (NLNK) at Buy; See Near-Term Catalyst

June 1, 2012 7:14 AM EDT
Get Alerts NLNK Hot Sheet
Price: $11.33 +5.00%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NLNK Now!
Join SI Premium – FREE
(Updated - June 1, 2012 8:24 AM EDT)

Canaccord Genuity assumes coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $23.00.

Analyst, Salveen Richter, said, "The key value driver is HyperAcute Pancreas (HAP) – a novel immunotherapy in P3 clinical trial for surgically-resected pancreatic cancer. A positive P2 (we recognize it was a single-arm study) in addition to the novel cancer vaccine platform are encouraging as we look toward P3 data (first interim analysis in late-2012/early-2013E). We model for peak worldwide HAP sales of $850M in 2020, of which $635M is recognized by NLNK. We view the remainder of the pipeline as a free-call option. While NLNK shares are up ~81% YTD, we believe long-term P2 overall survival data at ASCO (June 4) could serve as a near-term catalyst."

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $12.76 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Add Your Comment